The influences of Taiwan's generic grouping price policy on drug prices and expenditures: Evidence from analysing the consumption of the three most-used classes of cardiovascular drugs

BMC Public Health

Volumn 8, Issue , 2008, Pages

  Chen, Chi Liang ^a,b   Chen, Likwang ^c,d   Yang, Wei Chih ^c  

^a CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRESCRIPTION; REIMBURSEMENT; TAIWAN; CARDIOVASCULAR DISEASE; ECONOMICS; FEE; HEALTH CARE COST; STATISTICAL MODEL; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG COSTS; DRUGS, GENERIC; FEE SCHEDULES; HEALTH EXPENDITURES; HUMANS; LINEAR MODELS; TAIWAN;

EID: 43549113355     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-8-118     Document Type: Article

References (21)

1. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience. YJ Chou WC Yip CH Lee N Huang YP Sun HJ Chang, Health Policy Plan 2003 18 316 332 10.1093/heapol/czg038 12917273
2. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. SZ Liu JC Romeis, Med Care 2003 41 1331 1342 10.1097/01.MLR.0000100579.91550.C4 14668666
3. Changes in drug utilization following the outpatient prescription drug cost-sharing program - evidence from Taiwan's elderly. SZ Liu JC Romeis, Health policy 2004 68 277 287 10.1016/j.healthpol.2003.12.013 15113639
4. The pharmaceutical industry. FM Scherer, Handbook of Health Economics New York: Elsevier Science Press, Culyer AJ, JP N, 2000 1 1297 1336 10.1016/S1574-0064(00)80038-4
5. SO Schweitzer, Pharmaceutical Economics and Policy Oxford: Oxford University Press 1997
6. The drug budget silo mentality in Europe: an overview. L Garrison A Towse, Value health 2003 6 Suppl 1 S1 9 10.1046/j.1524-4733.6.s1.1.x 12846921
7. Reforming pharmaceutical policies in the European Union: a "penguin effect"? AM Guillén L Cabiedes, Int J Health Serv 2003 33 1 28 10.2190/1JC6-FRL4-QM2L-QN6E 12641260
8. FR Lichtenberg, The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey National Bureau of Economic Research Press 2001
9. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. E Mossialos A Oliver, Int J Health Plann Manage 2005 20 291 306 10.1002/hpm.816 16335079
10. General principles. http://www.nhi.gov.tw/webdata/AttachFiles/ Attach_8556_2_chi65-1.pdf
11. Guidelines of price adjustment for National Health Insurance reimbursed drugs. http://www.nhi.gov.tw/webdata/AttachFiles/Attach_8559_2_chi65-4.pdf
12. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. YC Lee MC Yang YT Huang CH Liu SB Chen, Pharmacoeconomics 2006 24 891 902 10.2165/00019053-200624090-00006 16942123
13. Principles on drug reimbursement price approval ofNational Health Insurance. http://www.nhi.gov.tw/webdata/AttachFiles/Attach_8558_2_chi65-3.pdf
14. JM Wooldridge, Introductory Econometrics: A Modern Approach Mason: South-Weatern Press 2 2003
15. Stata Corporation, Stata User' s Guide Release 7 Texas: Stata Press 2001
16. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. P Grootendorst D Stewart, Health Econ 2006 15 735 742 10.1002/hec.1103 16498702
17. The German experience in reference pricing. G Giuliani G Selke L Garattini, Health policy 1998 44 73 85 10.1016/S0168-8510(98)00012-8 10180203
18. Incentives and pharmaceutical reimbursement reforms in Spain. J Puig-Junoy, Health Policy 2004 67 149 165 10.1016/S0168-8510(03)00113-1 14720633
19. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Z Kaló N Muszbek J Bodrogi J Bidló Health Policy 2007 80 402 412 10.1016/j.healthpol.2006.04.002 16730848
20. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. K Andersson G Bergström MG Petzold A Carlsten, Health Policy 2007 81 376 384 10.1016/j.healthpol.2006.07.005 16945449
21. An exploration of pharmaceutical profit for health care providers. LT Tan YC Hong CR Hsieh, Proceedings of the 2005 IEAS Working Paper: May 2005; Taipei 2005